Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis | Zendy

Ganesh Raghu | Zendy; Bernt van den Blink | Zendy; Mark J. Hamblin | Zendy; Alison Brown | Zendy; Jeffrey A. Golden | Zendy; Lawrence Ho | Zendy; Marlies Wijsenbeek | Zendy; Martina Vašáková | Zendy; Alberto Pesci | Zendy; Danielle AntinOzerkis | Zendy; Keith C. Meyer | Zendy; Michael Kreuter | Zendy; H. Santin-Janin | Zendy; Geert-Jan Mulder | Zendy; Brian J. Bartholmai | Zendy; Renu Gupta | Zendy; Luca Richeldi | Zendy

Open Access

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis

Author(s) -

Ganesh Raghu,

Bernt van den Blink,

Mark J. Hamblin,

Alison Brown,

Jeffrey A. Golden,

Lawrence Ho,

Marlies Wijsenbeek,

Martina Vašáková,

Alberto Pesci,

Danielle AntinOzerkis,

Keith C. Meyer,

Michael Kreuter,

H. Santin-Janin,

Geert-Jan Mulder,

Brian J. Bartholmai,

Renu Gupta,

Luca Richeldi

Publication year - 2018

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2018.6129

Subject(s) - medicine , vital capacity , dlco , placebo , idiopathic pulmonary fibrosis , clinical endpoint , lung , diffusing capacity , interstitial lung disease , surgery , clinical trial , gastroenterology , pathology , lung function , alternative medicine

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research